牛牛AI助理已提取核心訊息
EyePoint Pharmaceuticals, Inc. reported its financial outcomes for the fourth quarter and full year ended December 31, 2023, on March 7, 2024. The company announced significant progress in its clinical trials, including positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD, which met all primary and secondary endpoints. The initiation of the first Phase 3 clinical trial for EYP-1901 is expected in the second half of 2024. EyePoint also dosed the first patient in the Phase 2 VERONA trial for diabetic macular edema (DME), with topline data expected in the first quarter of 2025. Additionally, topline data from the Phase 2 PAVIA trial in NPDR is anticipated in the second quarter of 2024. The company appointed Dr. Ramiro Ribeiro as Chief Medical Officer...Show More
EyePoint Pharmaceuticals, Inc. reported its financial outcomes for the fourth quarter and full year ended December 31, 2023, on March 7, 2024. The company announced significant progress in its clinical trials, including positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD, which met all primary and secondary endpoints. The initiation of the first Phase 3 clinical trial for EYP-1901 is expected in the second half of 2024. EyePoint also dosed the first patient in the Phase 2 VERONA trial for diabetic macular edema (DME), with topline data expected in the first quarter of 2025. Additionally, topline data from the Phase 2 PAVIA trial in NPDR is anticipated in the second quarter of 2024. The company appointed Dr. Ramiro Ribeiro as Chief Medical Officer and reported a strong financial position with $331 million in cash and investments as of December 31, 2023. This financial stability is expected to fund operations through the topline data of Phase 3 trials for EYP-1901 for wet AMD in 2026. Total net revenue for the fourth quarter was $14.0 million, a significant increase from the previous year's quarter. The company also completed an upsized underwritten public offering, raising $230 million in December. EyePoint's shares are traded on the Nasdaq Global Market under the symbol EYPT.
EyePoint Pharmicals, Inc.於2024年3月7日公佈了截至2023年12月31日的第四季度和全年財務業績。該公司宣佈其臨床試驗取得重大進展，包括溼性 AMD 中 EYP-1901 的 2 期 DAVIO 2 試驗的積極有效性和安全性數據，該試驗符合所有主要和次要終點。EYP-1901 的首個 3 期臨床試驗預計將於 2024 年下半年啓動。EyePoint還爲VERONA糖尿病黃斑水腫（DME）的2期試驗中的第一位患者進行了給藥，預計將在2025年第一季度公佈頂部數據。此外，NPDR第二階段PAVIA試驗的主要數據預計將在2024年第二季度公佈。該公司任命拉米羅·裏貝羅博...展開全部
EyePoint Pharmicals, Inc.於2024年3月7日公佈了截至2023年12月31日的第四季度和全年財務業績。該公司宣佈其臨床試驗取得重大進展，包括溼性 AMD 中 EYP-1901 的 2 期 DAVIO 2 試驗的積極有效性和安全性數據，該試驗符合所有主要和次要終點。EYP-1901 的首個 3 期臨床試驗預計將於 2024 年下半年啓動。EyePoint還爲VERONA糖尿病黃斑水腫（DME）的2期試驗中的第一位患者進行了給藥，預計將在2025年第一季度公佈頂部數據。此外，NPDR第二階段PAVIA試驗的主要數據預計將在2024年第二季度公佈。該公司任命拉米羅·裏貝羅博士爲首席醫療官，並報告稱，截至2023年12月31日，其財務狀況良好，現金和投資爲3.31億美元。這種財務穩定預計將通過 2026 年溼型 AMD EYP-1901 三期試驗的主要數據爲運營提供資金。第四季度的總淨收入爲1400萬美元，比上一季度大幅增長。該公司還完成了規模擴大的承銷公開募股，在12月籌集了2.3億美元。EyePoint的股票在納斯達克全球市場上市，股票代碼爲EYPT。
有用
沒用